Home › Research › Treatments
Transkript zur Episode „Lecanemab“
Denis Nößler, Martin Scherer, Thomas Duning. EvidenzUpdate, 2025-10-09
Topic: Brain proteins, microglia and lab models
Nößler: Selten hat die Neuanführung eines Arzneimittels so ein großes Medienecho ausgelöst wie jüngst der Markteintritt von Lecanemab und jetzt die Zulassung von Donanemab. Doch was können wir von diesen Alzheimer-Therapien erwarten? Sind sie die Gamechanger oder vielleicht doch nur Hype? Sind sie vielleicht sogar eine Gefahr für die Versorgung? Sprechen wir drüber, und zwar heute. Und damit herzlich willkommen zu einer Live-Episode des EvidenzUpdate-Podcasts. Wir das sind ... Scherer: Martin Scherer. Nößler: Past-Präsident der Deutschen Gesellschaft für Allgemeinmedizin und Familienmedizin, der DEGAM, und Direktor des Instituts und Poliklinik für Allgemeinmedizin am UKE in Hamburg. Und heute ist bei uns ... Duning: Thomas Duning. Nößler: Chefarzt der Klinik für Neurologie am Klinikum Bremen-Ost und Mitglied der Kommission Demenz und kognitive Neurologie in der Deutschen Gesellschaft für Neurologie, der DGN. Und hier Mikro ist Denis Nößler. Moin, Herr Duning, moin, Herr Scherer. Scherer: M…
Key findings
- Sind sie die Gamechanger oder vielleicht doch nur Hype?
- Sind sie vielleicht sogar eine Gefahr für die Versorgung?
- Und damit herzlich willkommen zu einer Live-Episode des EvidenzUpdate-Podcasts.
- Nößler: Past-Präsident der Deutschen Gesellschaft für Allgemeinmedizin und Familienmedizin, der DEGAM, und Direktor des Instituts und Poliklinik für Allgemeinmedizin am UKE in Hamburg.
- Nößler: Chefarzt der Klinik für Neurologie am Klinikum Bremen-Ost und Mitglied der Kommission Demenz und kognitive Neurologie in der Deutschen Gesellschaft für Neurologie, der DGN.
Why it matters
This podcast transcript discusses whether lecanemab and donanemab are genuine advances or hype, and whether they might even pose a risk to care. It does not report new trial results or provide evidence on treating, curing or preventing Alzheimer's disease.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 26/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on institution's track record, so that was left out: it earned 25 of the 97 points we could judge it on, which is 26 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (EvidenzUpdate) |
| Journal's citation record | 0 / 4 | EvidenzUpdate: journal h-index 1 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Thomas Duning: h-index 39 (OpenAlex, whole career) |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | 0 / 3 | OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 25 / 97 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 25 of the 97 points we could judge it on is 26 out of 100. |
| Total | 26 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
APA 7th
Nößler, D., Scherer, M., & Duning, T. (2025). Transkript zur Episode „Lecanemab“. EvidenzUpdate. https://doi.org/10.69156/trx.001/2025.10.00152
Vancouver
Nößler D, Scherer M, Duning T. Transkript zur Episode „Lecanemab“. EvidenzUpdate. 2025. doi:10.69156/trx.001/2025.10.00152.
BibTeX
@article{nossler2025-52ec276c,
author = {Nößler, Denis and Scherer, Martin and Duning, Thomas},
title = {{Transkript zur Episode „Lecanemab“}},
journal = {EvidenzUpdate},
year = {2025},
doi = {10.69156/trx.001/2025.10.00152},
url = {https://doi.org/10.69156/trx.001/2025.10.00152}
}